CGEN vs. KOD, VCXB, ELEV, GNFT, ZURA, IPHA, XFOR, IPSC, CLLS, and SCLX
Should you be buying Compugen stock or one of its competitors? The main competitors of Compugen include Kodiak Sciences (KOD), 10X Capital Venture Acquisition Corp. III (VCXB), Elevation Oncology (ELEV), Genfit (GNFT), Zura Bio (ZURA), Innate Pharma (IPHA), X4 Pharmaceuticals (XFOR), Century Therapeutics (IPSC), Cellectis (CLLS), and Scilex (SCLX). These companies are all part of the "medical" sector.
Compugen (NASDAQ:CGEN) and Kodiak Sciences (NASDAQ:KOD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.
In the previous week, Kodiak Sciences had 2 more articles in the media than Compugen. MarketBeat recorded 6 mentions for Kodiak Sciences and 4 mentions for Compugen. Kodiak Sciences' average media sentiment score of 0.45 beat Compugen's score of 0.32 indicating that Kodiak Sciences is being referred to more favorably in the news media.
Compugen has higher revenue and earnings than Kodiak Sciences. Compugen is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.
Compugen's return on equity of -30.01% beat Kodiak Sciences' return on equity.
Compugen has a beta of 2.63, meaning that its share price is 163% more volatile than the S&P 500. Comparatively, Kodiak Sciences has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500.
12.2% of Compugen shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 9.5% of Compugen shares are held by company insiders. Comparatively, 45.4% of Kodiak Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Compugen received 285 more outperform votes than Kodiak Sciences when rated by MarketBeat users. Likewise, 64.47% of users gave Compugen an outperform vote while only 28.13% of users gave Kodiak Sciences an outperform vote.
Compugen currently has a consensus price target of $4.00, indicating a potential upside of 101.01%. Kodiak Sciences has a consensus price target of $5.50, indicating a potential upside of 55.81%. Given Compugen's stronger consensus rating and higher probable upside, research analysts clearly believe Compugen is more favorable than Kodiak Sciences.
Summary
Compugen beats Kodiak Sciences on 11 of the 16 factors compared between the two stocks.
Get Compugen News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Compugen Competitors List
Related Companies and Tools
